Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808918) titled 'Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Shandong Suncadia Medicine Co., Ltd.
Condition:
Obese and Metabolic Disorders
Intervention:
Drug: HRS-1597
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 78
Countries of Recruitment:
China
To know m...